Indian Journal of Surgical Oncology

, Volume 6, Issue 1, pp 75–81

Review: The Role of Hyperthermia in Treating Pancreatic Tumors

Review Article

Abstract

There is only marginal improvement in outcome of treating pancreatic cancer in the last two decades. Time to open up and have a fresh look at complementary adjuvant treatment options. Hyperthermia may be one such option. Hyperthermic intraperitoneal chemotherapy (HIPEC) predominantly as a intrasurgical procedure has already proved its justification. Non-invasive loco regional hyperthermia as complement to either chemo or radiation has not yet reached a comparable status of evidence. However the potential to eventually grow into such evidence is already clearly observable. This review presents the various methodologies available for hyperthermia, covers the initial clinical data that has been published and gives an outlook to what can be expected in the next 2–3 years to come. Hyperthermia has the potential to significantly prolong life expectancies and this while maintaining a satisfying quality of life!

Keywords

Hyperthermia Pancreatic cancer Adjuvant heat treatment Palliative pain reduction 

References

  1. 1.
    Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMedGoogle Scholar
  2. 2.
    Riess H, Helm A, Niedergethmann M et al (2005) A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. Proc. ASCO; Abstr No: 4009Google Scholar
  3. 3.
    Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825CrossRefPubMedGoogle Scholar
  4. 4.
    Bakshandeh-Bath A, Stoltz AS, Homann N, Wagner T, Stölting S, Peters SO (2009) Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma. Anticancer Res 29(8):3069–3077PubMedGoogle Scholar
  5. 5.
    Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A, Sakamoto K, Kimura Y, Kobari M (1992) Intraoperative radiation therapy combined with hyperthermia against pancreatic carcinoma. Int J Oncol 1(7):795–798PubMedGoogle Scholar
  6. 6.
    Kouloulias VE, Kouvaris JR, Nikita KS, Golematis BC, Uzunoglu NK, Mystakidou K, Papavasiliou C, Vlahos L (2002) Intraoperative hyperthermia in conjunction with multi-schedule chemotherapy (pre-, intra- and post-operative), by-pass surgery, and post-operative radiotherapy for the management of unresectable pancreatic adenocarcinoma. Int J Hyperth 18(3):233–252CrossRefGoogle Scholar
  7. 7.
    Nakagawa A, Kamiyama Y, Matsui Y, Okuno M, Imamura A, Tu W, Nakagawa M, Kanemaki T, Takai S, Uetsuji S, Noro C, Kubo N, Nakase Y (1996) Selective thermocoagulation of unresectable malignant tumors using radiofrequency [Article in Japanese]. RiGan To Kagaku Ryoho 23(12):1651–1653Google Scholar
  8. 8.
    Sugarbaker PH, Stuart OA, Bijelic L (2011) Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol 2011:185092. doi:10.1155/2011/185092
  9. 9.
    Esquivel J et al (2006) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Ann Surg Oncol. doi:10.1245/s10434-006-9185-7 Google Scholar
  10. 10.
    Mi D-H, Li Z, Yang K-H, Cao N, Lethaby A, Tian J-H, Santesso N, Ma B, Chen Y-L, Liu Y-L (2013) Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperth 29(2):156–167CrossRefGoogle Scholar
  11. 11.
    Xiaoping L, Leizhen Z (2013) Advances of high intensity focused ultrasound (HIFU) for pancreatic cancer. Int J Hyperth 29(7):678–682CrossRefGoogle Scholar
  12. 12.
    Wang K, Chen L, Meng Z, Lin J, Zhou Z, Wang P, Chen Z (2012) High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis. Int J Hyperth 28(7):645–652CrossRefGoogle Scholar
  13. 13.
    Zhao H, Yang G, Wang D, Yu X, Zhang Y, Zhu J, Ji Y, Zhong B, Zhao W, Yang Z, Aziz F (2010) Concurrent gemticatbine and high-intensity fucused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs 21(4):447–452CrossRefPubMedGoogle Scholar
  14. 14.
    Van der Zee J, Vujaskovic Z, Kondo M, Sugarhara T (2008) Part I. Clinical hyperthermia. The Kadota Fund International Forum 2004 – clinical group consensus. Int J Hyperth 24(2):111–122CrossRefGoogle Scholar
  15. 15.
    Kandel S, Kloeters C, Meyer H, Hein P, Hilbig A, Rogalla P (2009) Whole-organ perfusion of the pancreas using dynamic volume CT in patients with primary pancreas carcinoma: acquisition technique, post-processing and initial results. Eur Radiol 19(11):2641–2646CrossRefPubMedGoogle Scholar
  16. 16.
    Fatehi D, van der Zee J, Notenboom A, van Rhoon GC (2007) Comparison of intratumor and intraluminal temperatures during locoregional deep hyperthermia of pelvic tumors. Strahlenther Onkol 183:479–486CrossRefPubMedGoogle Scholar
  17. 17.
    Hahn GM, Braun J, Har-Kedar I (1975) Thermochemotherapy: synergism between hyperthermia 42–43 degrees) and Adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A 72:937–940CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Raoof M, Cisneros BT, Corr SJ, Palalon F, Curley SA, Koshkina NV (2013) Tumor selective hyperthermia induced by short-wave capacitively-coupled RF electric-fields. PLoS One 4:8(7)Google Scholar
  19. 19.
    Adachi S, Kokura S, Okayama T, Ishikawa T, Takagi T, Handa O, Naito Y, Yoshikawa T (2009) Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines. Int J Hyperth 25(3):210–219CrossRefGoogle Scholar
  20. 20.
    Bull JM, Scott GL, Strebel FR, Nagle VL, Oliver D, Redwine M, Rowe RW, Ahn CW, Koch SM (2008) Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol. Int J Hyperth 24(8):649–662CrossRefGoogle Scholar
  21. 21.
    Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L (2008) Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 68(11):4026–4030CrossRefPubMedGoogle Scholar
  22. 22.
    Horsman MR, Overgaard J (2007) Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol 19:418–426CrossRefGoogle Scholar
  23. 23.
    Rubner Y, Wunderlich R, Rühle PF, Kulzer L, Werthmöller N, Frey B, Weiss EM, Keilholz L, Fietkau R, Gaip US (2012) How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol 2:75CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Hager ED, Migeod F, Koomagi R, Schrittwieser G, Krautgartner I (2006) Multimodal complementary therapy for advanced pancreas carcinoma; translation of publication of Deutsche. Zeitschrift für Onkologie 38:100–107CrossRefGoogle Scholar
  25. 25.
    Mueller-Huebenthal B (2010) Hyperthermia and gemcitabine for the treatment of advanced inoperable pancreatic cancer: a retrospective analysis of 25 cases. Presentation at the 6th binneal conference of Indian Association of Hyperthermia Oncology IAHOM; Jan 2010 Bangalore. (Updated data to be published 2014)Google Scholar
  26. 26.
    Sridhar PS (2012) Pain reduction in hyperthermia: 10 cases. Presentation at the 7th biennal conference of IAHOM, Febr. 2012 IndoreGoogle Scholar
  27. 27.
    Lee GY, Qian WP, Wang L, Wang YA, Staley CA, Satpathy M, Nie S, Mao H, Yang L (2013) Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 7(3):2078–2089CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Kim DH, Guo Y, Zhang Z, Procissi D, Nicolai J, Omary RA, Larson AC (2013) Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia. Adv Healthc Mater 3(5):714–24. doi:10.1002/adhm.201300209
  29. 29.
    McDaniel JR, Dewhirst MW, Chilkoti A (2013) Actively targeting solid tumours with thermoresponsive drug delivery systems that respond to mild hyperthermia. Int J Hyperth 29(6):501–510CrossRefGoogle Scholar
  30. 30.
    Zhang LP, Nie Q, Kang JB, Wang B, Cai CL, Li JG, Qi WJ (2008) Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer. Ai Zheng 27(11):1204–1207, Article in ChinesePubMedGoogle Scholar
  31. 31.
    Maluta S, Schaffer M, Pioli F, Dall’oglio S, Pasetto S, Schaffer PM, Weber B, Giri MG (2011) Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: an open-label comparative cohort trial. Strahlenther Onkol 187(10):619–625CrossRefPubMedGoogle Scholar
  32. 32.
    Ishikawa T, Kokura S, Sakamoto N et al (2012) Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer. Int J Hyperth 28(7):597–604CrossRefGoogle Scholar
  33. 33.
    Tschoep-Lechner KE, Milani V, Berger F, Dieterle N, Abdel-Rahman S, Salat C, Issels RD (2013) Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperth 29(1):8–16CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2014

Authors and Affiliations

  1. 1.Research & Development Celsius42+MannheimGermany
  2. 2.Oncology, Paracelsus KlinikZurich-RichterswilSwitzerland

Personalised recommendations